Innovate UK (part of UKRI), working with DSIT and Lilly, will invest up to £85m in obesity pathway innovations (£50m DSIT, £35m Lilly, incl. £10m ring-fenced for devolved administrations). Strand 3 funds combined “access & management” and “care pathway” services, creating community/primary-care weight-management pathways that are holistic, clinically appropriate, scalable and resource-efficient, aligned to NICE NG246 and SIGN. Applicants must show end-to-end pathway design, system readiness by 1 Aug 2026, robust clinical/information governance, sustainability beyond the grant, and transparency about Lilly’s co-funding (no patient data shared with Lilly).

email@streets.co.uk.
+01234 567 894
Alternatively
Give us a ring on or drop us an email at . Our offices might
be based in UK, but we proudly serve clients across the UK and Europe.

